Reported Earlier, Astellas' PADCEV In Combination With KEYTRUDA Approved By European Commission, For First-Line Treatment Of Advanced Urothelial Cancer
Portfolio Pulse from Benzinga Newsdesk
The European Commission has approved Astellas' PADCEV in combination with KEYTRUDA for the first-line treatment of advanced urothelial cancer. This regimen has shown superiority over the traditional platinum-containing chemotherapy, based on positive results from the Phase 3 EV-302 trial.
August 28, 2024 | 6:53 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Astellas' PADCEV, in combination with KEYTRUDA, has been approved by the European Commission for advanced urothelial cancer treatment, marking a significant advancement over traditional chemotherapy.
The approval of PADCEV in combination with KEYTRUDA by the European Commission is a significant milestone for Astellas, as it offers a new treatment option that has demonstrated superior results compared to the long-standing standard of care. This approval is likely to positively impact Astellas' market position and revenue potential in the oncology sector.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100